Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H14N8O5S2 |
| Molecular Weight | 438.442 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CN=[N+]=[N-])=C(N2C1=O)C(O)=O)C3=CSC(N)=N3
InChI
InChIKey=RIBNLVJVYUATJJ-WRGDFVOVSA-N
InChI=1S/C14H14N8O5S2/c1-27-20-7(6-4-29-14(15)18-6)10(23)19-8-11(24)22-9(13(25)26)5(2-17-21-16)3-28-12(8)22/h4,8,12H,2-3H2,1H3,(H2,15,18)(H,19,23)(H,25,26)/b20-7-/t8-,12-/m1/s1
| Molecular Formula | C14H14N8O5S2 |
| Molecular Weight | 438.442 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 19:35:23 GMT 2025
by
admin
on
Wed Apr 02 19:35:23 GMT 2025
|
| Record UNII |
B4A3RZQ8N3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
B4A3RZQ8N3
Created by
admin on Wed Apr 02 19:35:23 GMT 2025 , Edited by admin on Wed Apr 02 19:35:23 GMT 2025
|
PRIMARY | |||
|
72889-61-3
Created by
admin on Wed Apr 02 19:35:23 GMT 2025 , Edited by admin on Wed Apr 02 19:35:23 GMT 2025
|
PRIMARY | |||
|
6336466
Created by
admin on Wed Apr 02 19:35:23 GMT 2025 , Edited by admin on Wed Apr 02 19:35:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
MIC90
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Prevotella, Porphyromonas, Peptostreptococcus, Fusobacterium and Clostridium
spp. were susceptible to Ro 40-6890, with few exceptions. Due to its lack of activity against the
major pathogens of the Bacteroides fragilis
group, Ro 40-6890 does not promise to be of
major use in the treatment of infections caused by
anaerobes.
|